Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof of concept for potential once-weekly oral administration. Preclinical…
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…
June 20, 2025 19:30 ET | Source: Structure Therapeutics Inc. SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics…
IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic…
June 18, 2025 16:30 ET | Source: Cellectar Biosciences, Inc. FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar…
COPENHAGEN, Denmark, June 18, 2025 /PRNewswire/ -- Droplet IV today announced the successful completion of a $2 million funding round…
CAESAREA, Israel, June 17, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature…
BOCA RATON, Fla.--(BUSINESS WIRE)--#AndrewQueen--Integrated Dermatology, the country’s largest independent dermatology provider, proudly announces the addition of Shayan Cheraghlou, MD, FAAD,…
XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL…
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…